Main clinical and laboratory characteristics of training and internal validation sets
| Characteristic . | Training set . | Internal validation set . | Total . |
|---|---|---|---|
| N (%) | 535 (60) | 356 (40) | 891 (100) |
| Median age, y (range) | 54.4 (14.8-91.0) | 56.8 (12.9-85.7) | 55.7 (12.9-91.0) |
| Male/female, n (%) | 218/318 (41/59) | 152/203 (43/57) | 370/521 (42/58) |
| Median leukocyte count, × 109/L (5th-95th percentile) | 8.5 (5.3-14.2) | 8.9 (5.7-13.8) | 8.6 (5.3-14.2) |
| Median hemoglobin, g/dL (5th-95th percentile) | 14.1 (11.9-16.1) | 14.1 (12.0-16.1) | 14.1 (11.9-16.1) |
| Median platelets, × 109/L (5th-95th percentile) | 771 (500-1464) | 784 (506-1399) | 774 (500-1464) |
| Cardiovascular risk factors, n (%) | 118 (22) | 69 (19) | 187 (21) |
| JAK2V617F-positive, n (%) | 248 (62%) | 174 (61%) | 422 (61%) |
| Cases evaluated, n | 403 | 287 | 690 |
| Previous thrombosis, n (%) | 107 (20) | 74 (21) | 181 (20) |
| Arterial | 80 (15) | 51 (14) | 129 (14) |
| Venous | 27 (5) | 23 (7) | 62 (6) |
| Median follow-up, y (range) | 6.5 (0-26) | 6.1 (0-27) | 6.2 (0-27) |
| Treatments, n (%) | |||
| Cytoreductive therapy | 286 (53) | 195 (55) | 481(54) |
| Aspirin use | 339 (63) | 224 (63) | 563 (63) |
| Characteristic . | Training set . | Internal validation set . | Total . |
|---|---|---|---|
| N (%) | 535 (60) | 356 (40) | 891 (100) |
| Median age, y (range) | 54.4 (14.8-91.0) | 56.8 (12.9-85.7) | 55.7 (12.9-91.0) |
| Male/female, n (%) | 218/318 (41/59) | 152/203 (43/57) | 370/521 (42/58) |
| Median leukocyte count, × 109/L (5th-95th percentile) | 8.5 (5.3-14.2) | 8.9 (5.7-13.8) | 8.6 (5.3-14.2) |
| Median hemoglobin, g/dL (5th-95th percentile) | 14.1 (11.9-16.1) | 14.1 (12.0-16.1) | 14.1 (11.9-16.1) |
| Median platelets, × 109/L (5th-95th percentile) | 771 (500-1464) | 784 (506-1399) | 774 (500-1464) |
| Cardiovascular risk factors, n (%) | 118 (22) | 69 (19) | 187 (21) |
| JAK2V617F-positive, n (%) | 248 (62%) | 174 (61%) | 422 (61%) |
| Cases evaluated, n | 403 | 287 | 690 |
| Previous thrombosis, n (%) | 107 (20) | 74 (21) | 181 (20) |
| Arterial | 80 (15) | 51 (14) | 129 (14) |
| Venous | 27 (5) | 23 (7) | 62 (6) |
| Median follow-up, y (range) | 6.5 (0-26) | 6.1 (0-27) | 6.2 (0-27) |
| Treatments, n (%) | |||
| Cytoreductive therapy | 286 (53) | 195 (55) | 481(54) |
| Aspirin use | 339 (63) | 224 (63) | 563 (63) |